Category: | Health, |
---|---|
Address: | 500 Soldiers Field Rd, Allston, MA 02134, USA |
Postal code: | 02134 |
Phone: | (617) 562-4500 |
Website: | http://www.sanofigenzyme.com/ |
Cool
Get directions, reviews and information for Sanofi Genzyme in Allston, MA. Reviews. (617) 562-4500 Website.
Jill Ilsley Fellowship Director Sanofi Genzyme PharmDFellowships@sanofi.com.
However, Sanofi and Genzyme appear to have exceeded expectations in the Biotech world. The renamed Sanofi Genzyme division will be led by David Meeker and will include a pair of the company's candidates, sarilumab and dupilumab, developed by Regeneron.
Sanofi Genzyme Company. 500 Kendall Street Cambridge, 02142. Fax: (617) 252-7600. Close more info about Sanofi Genzyme Company.
CYN 2020 Virksomhed - Sanofi Genzyme 3D Model.
Sanofi Genzyme Atrium in Beijing, China. Courtesy RMJM Hillier. In 2011 Sanofi Genzyme, one of the world's largest biotechnology companies, built a new research and development center in Beijing's Zhongguancun Life Science Park, the city's emerging research, development and technology hub.
About Genzyme, a Sanofi Company. Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. All rights reserved. Media Contact: Genzyme Ingrid Mitchell, 617-768-6699 Ingrid.Mitchell@genzyme.com.
Senior Dir:Investments. Sanofi-Genzyme BioVentures. Sanofi-Genzyme BioVentures (SGBV) operates as a venture capital firm. The Company invests in life-science companies. PHONE. 1-617-768-6096. WEBSITE. www.sanofigenzymebioventures.com.
Sanofi Genzyme's retreat now resembles a desertion. On Monday, Voyager $VYGR said Sanofi Genzyme is walking away from options to acquire US co-commercialization rights and ex-US development and commercialization rights to experimental Huntington's disease drug VY-HTT01 and...
Sanofi, Genzyme Talk A Little More Before Getting Together. Media reports say that Sanofi-Aventis and Genzyme are in the final stages of takeover negotiations, and a Sanofi-Genzyme Talks Likely To Drag On And On. Acquisition talks between the pharma and the biotech are a Kabuki in slow motion.